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Abstract
The Saccharomyces cerevisiae High-Osmolarity Glycerol (HOG) pathway is a conserved mitogen-activated protein kinase
(MAPK) signal transduction system that often serves as a model to analyze systems level properties of MAPK signaling.
Hog1, the MAPK of the HOG-pathway, can be activated by various environmental cues and it controls transcription,
translation, transport, and cell cycle adaptations in response to stress conditions. A powerful means to study signaling in
living cells is to use kinase inhibitors; however, no inhibitor targeting wild-type Hog1 exists to date. Herein, we describe the
design, synthesis, and biological application of small molecule inhibitors that are cell-permeable, fast-acting, and highly
efficient against wild-type Hog1. These compounds are potent inhibitors of Hog1 kinase activity both in vitro and in vivo.
Next, we use these novel inhibitors to pinpoint the time of Hog1 action during recovery from G1 checkpoint arrest,
providing further evidence for a specific role of Hog1 in regulating cell cycle resumption during arsenite stress. Hence, we
describe a novel tool for chemical genetic analysis of MAPK signaling and provide novel insights into Hog1 action.
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Introduction
Protein kinases have crucial roles in virtually all signaling pathways
and they regulate diverse cellular functions, such as cell cycle pro-
gression, apoptosis, metabolism, differentiation, cell morphology and
migration, and secretion of cellular proteins [1]. Many kinases are
highly conserved throughout the eukaryotic kingdoms and constitute
an important field of research because of their involvement in disease
processes. For instance, abnormal signaling is the cause of many
human diseases, while activation of signal transduction pathways is a
major survival response during drug therapies. The present under-
standing of cellular signal transduction is in most cases restricted to the
wiring schemes of signaling pathways, while little is known about their
dynamic operation and time-dependent parameters for signaling
output. The latter has been difficult to explore since traditional analy-
sis has relied upon gene deletion/knock-out mutants, and in such
mutants, cells can compensate for the lack of the kinase by rewiring
signaling pathways or by adapting by other means [2]. An alternative
approach is to use highly selective, cell-permeable, and fast-acting
inhibitors of individual kinases to systematically investigate the cellular
function of a kinase in real time.
Protein kinases share common sequences and structural ho-
mology in their ATP-binding sites. Many ATP competitive kinase
inhibitors lack selectivity because the catalytic cleft is highly
conserved in sequence and conformation [3]. Nevertheless, despite
this high degree of conservation in the ATP-binding site, highly
selective small molecules with favorable pharmaceutical properties
have been developed [4].
One approach that has been used successfully with high inhibition
selectivity is the so-called ASKA technology [5]. This approach
involves modifying a kinase inhibitor to eliminate its binding affinity for
its native target and subsequent mutation of a protein kinase to allow it
to recognize the orthogonal inhibitor. The basic idea relies on the
assumption that the so-called ‘‘gate-keeper’’ residue blocks access to an
additional hydrophobic pocket in the ATP cleft and that the mutation
(from a larger to a smaller residue, typically glycine) contributes to a
stronger binding of the orthogonal inhibitor. Shokat and colleagues
have used this approach extensively to study protein kinases [6].
Recently, ASKA technology has been used to identifynovel targets and
to provide novel insights into the mechanisms that control signaling
through the Saccharomyces cerevisiae (budding yeast) HOG MAPK
pathway [7,8,9].
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20012Although ASKA technology has turned out to be very useful for
studying protein kinases in general, it would be more convenient to
use wt kinase inhibitors and thereby circumvent the need to
generate cells that express the as version of the protein kinase of
interest. Furthermore, it cannot be excluded that the as-mutation
alters kinase activity and/or stability to some extent. Hence, by
interfering less with the natural biological system, the experimental
data will probably be more relevant. Therefore, we were interested
in the development of a specific wtHog1 inhibitor that would allow
us to study the dynamic behavior of this kinase.
Exposure of yeast to high osmolarity triggers rapid phosphor-
ylation, activation, and nuclear translocation of Hog1, the MAPK
of the HOG pathway [10,11,12]. In the nucleus, Hog1 associates
with stress-responsive promoters via specific transcription factors
and stimulates gene expression by recruiting general transcription
factors, chromatin-modifying enzymes, and RNA polymerase II
[10,11]. Activation of gene expression is not the sole mechanism
by which Hog1 controls osmoadaptation; a plasma membrane
anchored version of Hog1 is biologically active and such cells can
withstand osmotic stress [13]. Hog1 has been shown to regulate a
number of cytosolic proteins [14,15,16] and to delay cell cycle
progression by negatively regulating the activity of cyclin-depen-
dent kinase complexes through a number of different mechanisms
[17,18,19]. Hog1 is also activated in the presence of the metalloid
arsenite [As(III)], and its kinase activity is required for cell survival
during As(III) exposure. Interestingly, the dynamics of Hog1
activation by osmotic stress and As(III) are different, and As(III)-
activation does not involve a Hog1-dependent induction of gene
expression. Instead, Hog1 contributes to As(III) tolerance by
restricting As(III) uptake into cells and by controlling cell cycle
progression [14,20].
The MAPK p38 is the mammalian ortholog of yeast Hog1 and
is extensively studied due to its involvement in chronic
inflammatory diseases [21]. p38 is also activated by As(III) [22]
and triggers cell cycle arrest, differentiation, or mitochondrial
apoptotic cell death [23,24]. One class of selective p38 inhibitors is
the pyridinylimidazole-based compounds (SB) [25,26]. Several of
these compounds are highly potent and inhibit p38 at nanomolar
concentrations (Figure 1). However, these inhibitors cannot be
used for in vivo inhibition of Hog1 since they do not accumulate in
yeast cells (see Uptake of inhibitors by yeast cells). Recently, we
took advantage of the structural similarities between 4- and 5-
substituted 1,2,3-triazoles and pyridinylimidazole-based inhibitors
in the design of new inhibitors of p38, which prompted us to
explore the use of triazoles as potential Hog1 inhibitors [27].
Herein, we report the design, synthesis, and biological evaluation
of potent and selective 4- and 5-substituted 1,2,3-triazoles as
wtHog1 inhibitors. Using two of these novel inhibitors, we de-
monstrate that Hog1 controls the exit from As(III)-induced cell
cycle arrest.
Results and Discussion
Design
So far, there is no structural information (X-ray or NMR)
available for Hog1. Nonetheless, Hog1 is highly similar to mam-
malian p38a, with 51% identity at the amino acid level, and we
built homology models of Hog1 based on structural information
from crystallographic data for p38a (1a9u). The homology model
showed high conservation of the amino acid residues in the ATP-
binding cleft between Hog1 and p38a, suggesting that the binding
motif of inhibitors in p38a could potentially be used to guide the
development of Hog1 inhibitors.
A new series of 4- and 5-substituted 1,2,3-triazoles (compounds
4a–e) were designed to have amine functionality in the 2-position
of the pyridine ring that could potentially form an extra hydrogen
bond with the hinge region (Figure 2A). The new triazole com-
pounds 4a–e were docked into the homology model of Hog1
[28,29]. The binding mode of the amine-containing triazoles
(yellow) is similar to the binding mode of the SB203580 inhibitor
(a known inhibitor of p38a, p38b, and AKT/PKB; in blue); i.e.,
the 4-flourophenyl group interacts with hydrophobic region I and
the nitrogen in the pyridine group hydrogen bonds to the amide of
Gln103 in the hinge region (Figure 2B).
In addition, the docking studies showed that the amine fun-
ctionality hydrogen bonds to the carbonyl group of Gln103 in
the hinge region, which could potentially increase the binding
affinity [30].
Synthesis
Previously, we had recognized the Cu(I)-catalyzed azide-alkyne
1,3-dipolar [2+3]-cycloaddition reaction as the key step in forming
five-membered 4- and 5-substituted 1,2,3-triazoles, which can
easily be coupled via a Suzuki coupling to yield compounds that
have been evaluated as p38a inhibitors (compounds 1a–1e; see
Figure 1) [27]. By the use of the bifunctional 2-chloropyridine
boronic acid in the Suzuki coupling, the reaction sequence can be
extended via a Hartwig-Buchwald C-N bond coupling, yielding
the target compounds containing the amine substituent in the 2-
position of the pyridine ring (Figure 3) [31].
The synthesis of the target compounds is shown in Figure 4.
Compound 2 was prepared as previously described [27]. The
synthesis of the 4- and 5-substituted 1,2,3-triazole intermediate 3
was completed in high yield (89%) via a palladium-catalyzed
Suzuki coupling reaction between the halogenated 4-aryl substi-
tuted 5-iodo-1,2,3-triazole (1) and 2-chloropyridin-4-ylboronic
acid in the presence of Pd(PPh3)4 (2 mol%) and K2CO3 at
150uC in the microwave.
The subsequent Hartwig-Buchwald C-N bond coupling be-
tween 3 and various amines using 5 as a catalyst furnished the
target compounds 4a–e in good yields (64–74%, Figure 4).
Figure 1. p38 kinase inhibitors. SB 203580 is a pyridinyl imidazole
inhibitor of p38 MAPK that specifically blocks its kinase activity and is
widely used as a research tool. Compounds 1a–1e were recently
described as p38a inhibitors.
doi:10.1371/journal.pone.0020012.g001
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The effect of the compounds on Hog1 activity was evaluated
using in vitro kinase assays. For this, we incubated purified in vitro-
activated Hog1 together with a biotinylated peptide as a substrate.
The initial assays were performed in the presence of 0.1 mM of the
compounds 1a–1e, 4a–4e, and SB203580, and the efficacy of
these compounds to reduce phosphorylation of the Hog1 substrate
was measured (Figure 5A).
We found that compounds 1a–1e were less efficient in
inhibiting substrate phosphorylation (50–70% remaining activity)
compared to the reference compound SB203580 (40% remaining
activity). Of the new compounds 4a–4e, compound 4c had a
weak effect on Hog1 activity (about 75% remaining activity)
while 4d and 4e were similar to SB203580 (35–40% remaining
activity). Importantly, compounds 4a and 4b showed a significant
decrease in substrate phosphorylation at a concentration of
Figure 2. The ATP binding site of Hog1. A) Schematic picture of
the ATP binding site of Hog1 from homology modeling using p38a
(1a9u) as the template. B) Docking of triazole-based inhibitors 4a–e
(yellow) together with SB203580 (blue) into the ATP-binding site of
Hog1.
doi:10.1371/journal.pone.0020012.g002
Figure 3. Retro-synthetic analysis of the target compounds.
doi:10.1371/journal.pone.0020012.g003
Figure 4. Scheme for the synthesis of target compounds 4a–e.
doi:10.1371/journal.pone.0020012.g004
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tion compared to SB203580.
IC50 determination
In order to compare the potency of compounds 4a, 4b, and
SB203580, their IC50-values were determined. For this, we added
these inhibitors to kinase reactions at concentrations ranging from
0.10 nM to 10 mM, measured substrate phosphorylation, plotted
the remaining activity against inhibitor concentration, and cal-
culated the IC50-values (Figure 5B). The IC50-values for com-
pounds 4a and 4b were determined as 7.460.41 nM and
6.262.2 nM respectively, giving approximately 7-fold stronger
inhibition than the reference compound SB203580 (49.561.6
nM). Hence, 4a and 4b are more potent inhibitors of Hog1
activity in vitro compared to the reference inhibitor SB203580.
Uptake of inhibitors by yeast cells
To be useful in vivo, the inhibitors need to enter yeast cells. To
test this, a lawn of yeast cells was spread on solid medium and filter
discs containing various concentrations of compounds 4a, 4b, and
SB203580 were placed on top of the lawn (Figure 6A). Survival of
yeast cells in the presence of osmotic stress requires Hog1 activity;
hence, inhibition of Hog1 can be visualized by the formation of a
halo of non-proliferating cells around the filter discs in the
presence of osmotic stress. Thus, the size of the halo is a measure
of Hog1 inhibition in this assay.
When wild-type yeast was exposed to high osmolarity, a clear
halo was formed around compounds 4a and 4b at concentrations
down to 0.1 mM (Figure 6A). No growth inhibition was observed
around the filter discs in the absence of osmotic stress (Figure 6A),
indicating that these compounds are not toxic to cells at these
concentrations. In a reciprocal experiment, we tested whether
these compounds could alleviate growth inhibition caused by
overexpression of the kinases Ssk1 and Pbs2; these kinases act
upstream of Hog1 and their overexpression results in Hog1
hyperactivation. In turn, hyperactivated Hog1 inhibits growth
while inactivation of Hog1 (by deletion of the HOG1 gene) partially
suppresses the phenotypes caused by Ssk1 or Pbs2 overexpression
[32,33]. Importantly, the presence of 4a or 4b alleviated the
growth inhibition caused by Ssk1 and Pbs2 overexpression
(Figures 6B, S6 and S7), indicating that 4a and 4b are taken up
by cells and inhibit Hog1 activity.
In the case of SB203580, no halo was formed around osmo-
stressed cells (Figure 5A), indicating that this compound does not
enter cells or that it is efficiently exported. To distinguish between
these possibilities, we repeated the halo assay using the pdr5D
mutant that lacks a major multidrug export protein Pdr5 [34]. 4a
and 4b also inhibited Hog1 activity in pdr5D cells, since clear halos
were formed even at 0.02 mM (Figure S1). In contrast, no halo
was formed in the presence of SB203580, suggesting that it
does not accumulate in yeast cells. In order to study if the
pyridinylimidazole-based kinase inhibitors in general have a poor
uptake into yeast cells, we carried out another halo assay using
wild-type yeast cells and four different commercially available
pyridinylimidazole-based kinase inhibitors (Figure S2). We also
included a commercially available inhibitor with a completely
different structure that inhibits p38 MAP kinase by utilizing an
Figure 5. In vitro Hog1 kinase activity assays. (A) Efficacy of
compounds 1a–e, 4a–e, and SB203580. (B) IC50 curves for com-
pounds 4a, 4b, and SB203580. Kinase assays were performed in a
kinase buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 2 mM DTT)
containing 0.4 mg GST-Hog1, 0.2 mM ATP, 0.1 mCi/nmol [
32cP]ATP, and
100 mM peptide substrate, and Hog1 activity was determined as
described in the Experimental section. Kinase reactions were performed
in the presence of 0.1 mM inhibitor (A) or with a range of inhibitor
concentrations (B). The concentration of the DMSO vehicle was identical
in all reactions (1% final). The results are the average of three
independent experiments and the error bars represent the standard
deviation (s.d.).
doi:10.1371/journal.pone.0020012.g005
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are considered to be important tools for the study of p38 MAP
kinase function both in vivo and in vitro, and should be potentially
useful for studying Hog1 signaling. However, like SB203580 none
of these compounds demonstrated any growth inhibition in
the halo assay (Figure S2). The results clearly show that kinase
inhibitors developed to target human kinases are not automatically
useful for experiments in yeast cells although the homology
between the human target and the yeast counterpart is high.
Possible explanations for this difference between our pyridinyl-
triazole-based inhibitors and the commercial available
pyridinylimidazole-based inhibitors could be that the pyridinyl-
triazole-based inhibitors are recognized by transport proteins that
allow efficient uptake or/and pyridinylimidazole-based inhibitors
are recognized by transport proteins that allow efficient export of
these molecules. To sum up, 4a and 4b are efficiently taken up by
cells and can be used for inhibiting Hog1 activity in vivo.
In vivo activity
To characterize the action of these inhibitors in vivo, we first
monitored how 4a affects Hog1 translocation into the nucleus
upon osmotic stress, a process that requires Hog1 kinase activity
[9]. To do this, we transformed hog1D cells with a plasmid
expressing Hog1 fused to GFP (green fluorescent protein) under
the control of the endogenous HOG1 promoter and monitored the
Hog1-GFP fusion protein by fluorescence microscopy. Exposing
cells to 0.8 M sorbitol triggered a rapid accumulation of Hog1-
GFP in the nucleus (Figure 7A). In contrast, pre-treating cells with
5 mMo f4a prior to osmotic stress exposure prevented nuclear
accumulation of Hog1-GFP in the majority of the cells, suggesting
that 4a inhibits Hog1 kinase activity.
Next, we assessed Hog1 activation by monitoring its phosphor-
ylation state after osmotic stress by using antibodies that
specifically recognize phosphorylated Hog1. Hog1 was rapidly
and transiently phosphorylated in response to osmotic stress
(0.8 M sorbitol); phosphorylated Hog1 was visible at the 15
minute time point while Hog1 was effectively dephosphorylated
after 30 minutes (Figure 7B). Pre-treating cells with 1 mMo r5mM
of 4a prior to osmotic stress exposure resulted in sustained Hog1
phosphorylation (Figure 6B and data not shown). Previous studies
have demonstrated that Hog1 kinase activity is required to
promote its own dephosphorylation [8,9]. Consistently, a kinase-
dead version of Hog1 showed sustained phosphorylation in
response to osmotic stress ([9,35] and Figure S3). Hence, sustained
Hog1 phosphorylation in the presence of 4a indicates that this
compound inhibits Hog1 kinase activity.
Finally, we monitored expression of the STL1 gene whose
induction during osmotic stress is fully dependent on Hog1 activity
[36]. For this, we exposed cells that harbor the STL1 promoter
fused to the lacZ reporter gene (STL1-lacZ) to osmotic stress and
determined b-galactosidase activity as a read-out for Hog1 activity
(Figure 7C). Osmotic stress triggered a strong activation of STL1-
lacZ expression. However, pre-treating cells with 1 mMo f4a prior
to osmotic stress prevented induction of STL1-lacZ expression,
indicating that 4a interferes with Hog1 activity. Treating cells with
4b caused a similar inhibition of STL1-lacZ expression (Figure S4).
Collectively, these short-term (minutes to hours) assays (Figuress
7A–C) together with long-term (2–3 days; Figure 6) growth assays
clearly show that 4a (and also 4b) effectively inhibits Hog1 activity
in vivo.
Selectivity
Yeast has several MAPK pathways that are activated by various
stimuli, and cross-talk between these pathways exists [37,38].
Therefore, inhibitors that act on Hog1 should not target other
yeast MAPKs. In order to test selectivity of the novel inhibitors, we
did chemical genetic profiling of the yeast deletion mutant
collection and scored for mutants with reduced growth in the
presence of 500 mM 4a. This screen identified 32 mutants that
were at least 2-fold less abundant than the wild-type at the end of
the experiment (Table S1), supporting the notion that 4a does not
cause a general toxicity to cells. We next compared the set of
inhibitor-sensitive mutants to sets of genes/mutants that show a
negative genetic interaction with either of the five yeast MAPKs
(Hog1, Slt2, Kss1, Fus3, Smk1) (interaction data from [39,40]
Figure 6. Uptake of inhibitors by yeast cells. (A) A lawn of wild-
type yeast cells (BY4741 strain) was spread on solid medium in the
absence (control) or presence of osmotic stress (1.5 M sorbitol), and
filter discs containing various concentrations of 4a, 4b, and SB203580
were placed on top of the lawn. Inhibition of Hog1 activity could be
visualized by the formation of a halo of non-proliferating cells around
the filter discs in the presence of osmotic stress (1.5 M sorbitol). No
such halo was visible on control plates in the absence of osmotic stress.
Plates were incubated for 48 hours at 30uC. (B) 4a improves growth of
PBS2 overexpressing cells. Wild-type and hog1D cells (BY4743 strain)
were transformed with an empty plasmid or plasmid overexpressing
PBS2. Cells were grown in a microcultivation system in the absence or
presence of inhibitor as indicated.
doi:10.1371/journal.pone.0020012.g006
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negative genetic interaction gene-sets would indicate whether the
inhibitor targets a particular MAPK. Importantly, we found a
statistically significant overlap between those gene-sets for Hog1
(p=0.00127; Table S1) but not for any of the other MAPKs
(p.0.05), suggesting that 4a is selectively inhibiting Hog1.
To test selectivity in a different way, we exposed cells to a-
factor, a condition that activates the Fus3 and Kss1 MAPKs, and
monitored expression of the FUS1-lacZ reporter gene as a read-out
for Fus3 and Kss1 kinase activities (Figure 6D). Exposing cells to a-
factor resulted in strong activation of FUS1-lacZ expression. Pre-
treating cells with 4a did not reduce FUS1-lacZ expression in
response to a-factor. These data suggest that 4a does not inhibit
the Fus3 and Kss1 MAPKs, at least not at concentrations that fully
inhibit Hog1, as judged by the lack of osmotic stress-induced
STL1-lacZ expression in the presence of 4a (Figure 7C). Hence, 4a
appears to selectively target the Hog1 kinase for inhibition.
Use of the novel inhibitors to elucidate the G1 checkpoint
function of Hog1
We recently demonstrated that yeast cells lacking Hog1 are
highly As(III) sensitive [14] and exhibit a persistent arrest in the G1
phase of the cell cycle due to accumulation of the cell cycle-
dependent kinase inhibitor Sic1 [14,20]. In contrast to previous
findings showing the involvement of Hog1 in promoting
hyperosmotic stress-induced G1 checkpoint arrest (18), our data
suggested that Hog1 is not required for cell cycle delay in G1 in the
presence of As(III), but instead plays a crucial role in cellular
recovery from As(III)-induced G1 cell cycle arrest. However, in
response to As(III) stress, Hog1 fulfills also other functions
unrelated to cell cycle regulation, like inhibition of As(III) influx
by affecting the transport activity of the Fps1 glycerol channel
[20]. Thus, by using the HOG1 deletion mutant (hog1D) only, we
could not pin-point neither time nor mechanism of Hog1 action
during G1 cell cycle delay and recovery. Nevertheless, we showed
with an analogue-sensitive mutant of Hog1 (Hog1-as) and 1-NM-
PP1 inhibitor, that lack of Hog1 kinase activity is responsible for
persistent G1 arrest in the presence of As(III) [20]. However, the
results of the cell cycle experiments with the Hog1-as allele were
confounded by the fact that in the absence of 1-NM-PP1, the
Hog1-as strain displayed much longer As(III)-induced G1 delay
than wild-type cells [14,20].
Having a novel and potent inhibitor of wild-type Hog1 at hand,
we wanted to identify the execution point of Hog1 function in
regulating the G1/S checkpoint in the presence of As(III). First, we
determined the kinetics of Hog1 activation in G1-synchronized
wild-type cells released from a-factor arrest in the presence of
0.5 mM As(III) by monitoring the level of phosphorylated Hog1
(Figure 8).
We found that Hog1 phosphorylation peaked within the first
30 minutes of As(III) exposure as previously shown for asynchro-
Figure 7. In vivo activity and selectivity of inhibitor 4a. (A) Nuclear accumulation of Hog1 is prevented in the presence of 4a. A plasmid
encoding a Hog1-GFP fusion protein was transformed into the hog1D mutant, and living cells were analyzed by fluorescence microscopy for Hog1
localization. Cells were either untreated or exposed to osmotic stress (0.8 M sorbitol). Inhibitor (5 mM) was added to cells 15 minutes before osmotic
stress was applied. (B) Hog1 dephosphorylation is prevented in the presence of 4a. Hog1 phosphorylation was monitored in cells exposed to osmotic
stress (0.8 M sorbitol) by Western blot analysis using an antibody specific to dually phosphorylated p38 MAPK, and an anti-Hog1 antibody was used
as a control. Inhibitor (5 mM) was added to cells 15 minutes before osmotic stress was applied. (C) Inhibition of Hog1-dependent gene expression.
Exponentially growing cells harboring the STL1-lacZ reporter were exposed to osmotic stress (0.8 M sorbitol) and assayed for b-galactosidase activity
as described in the Experimental section. Induced expression of the STL1 gene by osmotic stress required Hog1 but no other signal transduction
pathways. Inhibitor was added to cells at the indicated concentrations 10 minutes before osmotic stress was applied. The results are the average of
three independent experiments and the error bars represent standard deviation (s.d.). (D) 4a is selective for Hog1 inhibition since it does not affect
the Fus3/Kss1 MAPKs. Exponentially growing cells harboring the FUS1-lacZ reporter were exposed to a-factor (10 mM) and assayed for b-galactosidase
activity as described above. Induced expression of the FUS1 gene in response to a-factor required Fus3 and Kss1 but was independent of Hog1 [38].
doi:10.1371/journal.pone.0020012.g007
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activation was maintained for up to 180 minutes from a-factor
arrest release in the presence of 0.5 mM As(III), though it
gradually decreased from 90 minutes (Figure 8A). More impor-
tantly, the a -factor-nocodazole trap assay (to determine the
number of G1 cells versus post-G1 (S/G2/M) cells) performed on
the same culture as above (Figure 8A), revealed that in the
presence of As(III), wild-type cells started to enter S phase 80–
100 min from a-factor release (Figure 8B). Thus, when cells are
exposed to As(III) in G1, Hog1 is phosphorylated and hence
activated not only immediately after As(III) addition but also at
much later time points during the recovery from G1 arrest.
Next, we determined the effect of 4a or 4b on Hog1-dependent
cell cycle progression during As(III) exposure. Wild-type cells were
synchronized in G1 by a-factor, released in fresh medium
containing 0.5 mM As(III) in the presence of 1 mM inhibitor,
and analyzed by the a-factor-nocodazole trap assay (Figures 8B
and S5). The addition of 4a or 4b resulted in a persistent G1
delay, which was indistinguishable from that of hog1D cells.
Importantly, neither of the inhibitors had any effect on the G1/S
cell cycle transition in the absence of As(III) (Figures 8B and S5).
Knowing that Hog1 also has non-cell-cycle related functions
during As(III) stress [14] and having established the kinetics of
Hog1 activation in G1 upon As(III) addition (Figure 8A), we took
advantage of our inhibitors to show the execution role of Hog1 in
timely entry into the S phase. G1-synchronized cells were
resuspended in fresh medium in the presence of As(III), and
inhibitor was added 0, 40, 80, or 100 minutes after release
(Figures 8C and S5). Inhibition of Hog1 kinase activity prevented
entry into the S phase of any cell that still remained in G1 at
the time of inhibitor addition. In a reciprocal experiment,
G1-synchronized cells were released in the presence of As(III)
and inhibitor to execute a persistent G1 arrest followed by washing
out the inhibitor at the 120 minute time point (Figures 8D and S5).
After removal of inhibitor from the medium, cells gradually
entered the S phase despite the presence of As(III). Taken to-
gether, our new data obtained with inhibitors 4a and 4b strongly
support the notion that Hog1 kinase activity is specifically required
for the execution of G1 arrest release when the cell adapts to the
presence of As(III) and is ready to resume the cell cycle.
In conclusion, potent and fast acting inhibitors targeting the
wild-type version of the yeast MAPK Hog1 have been developed.
Our novel inhibitors (4a and 4b) are structurally related to
SB203580 (Figures 1 and 2), a commercially available inhibitor
of p38a, p38b, and AKT/PKB. Importantly, in contrast to
SB203580, both of our inhibitors enter yeast cells efficiently
(Figures 6, S1, S2, S6 and S7), allowing exploration of rapid signal
transduction events in living cells. Indeed, 4a and 4b inhibit Hog1
activity to similar levels, both in vitro and in vivo (Figures 5, 7, 8, S4
and S5). The yeast HOG pathway is one of the most studied
MAPK pathways, and the availability of these novel inhibitors for
rapid and selective inactivation of Hog1 will be essential to dissect
novel aspects of the signaling process as well as to define novel
biological roles for Hog1. Indeed, in this paper we successfully
used these inhibitors to pin-point the time of Hog1 action during
recovery from G1 checkpoint arrest, providing further evidence for
a specific role of Hog1 in regulating cell cycle resumption during
As(III) stress (Figures 8 and S5). Moreover, combination of 4a and
4b together with the as-kinase inhibitor 1-NM-PP1 opens the
possibility to simultaneously modulate the activities of two MAPK
pathways for studying signaling cross-talk. Finally, these com-
pounds may also prove of value for studying Hog1 signaling in
Figure 8. Hog1 kinase activity is required to relieve As(III)-induced G1 checkpoint arrest. (A) Kinetics of Hog1 activation during G1
checkpoint adaptation in response to As(III) stress. Hog1 phosphorylation was monitored as in Figure 6. (B) HOG1 deletion or the addition of 4b
resulted in persistent G1 arrest in the presence of As(III). (C) As(III)-induced G1 checkpoint delay can be prolonged by addition of 4b until just before
onset of the S phase. (D) Removal of 4b quickly relieves G1 arrest. Wild-type (W303-1A) and the isogenic HOG1 deletion mutant (hog1D) were
synchronized in G1 with 5 mM a-factor and released in fresh medium in the presence or absence of 0.5 mM sodium arsenite [As(III)]. 4b (1 mM) was
added as indicated. After washing out the inhibitor (in 7D), the cells were resuspended in fresh medium containing 0.5 mM As(III). The percentage of
cells that remained in G1 was determined by the a-factor-nocodazole trap assay.
doi:10.1371/journal.pone.0020012.g008
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Materials and Methods
General
1H (400 MHz) and
13C (100 MHz) NMR spectra were obtained
from a JEOL JNM-EX 400 spectrometer. Column chromatogra-
phy was performed by manual flash chromatography (wet packed
silica, 0.04–0.063 mm) or by automated column chromatography
on a Biotage SP-4 system using pre-packed columns. Microwave
reactions were performed in a Biotage Initiator reactor with a
fixed hold time. X-ray structures with inhibitors were used as the
starting point for all dockings. Docking was performed by using
Glide (Schro ¨dinger) with extra precision (XP) settings and
standard parameters for ligand docking [28,29].
Synthesis
4-(1-benzyl-4-(4-fluorophenyl)-1H-1,2,3-triazol-5-yl)-2-ch-
loropyridine (3a). The triazole halide (575 mg, 1.5 mmol) was
dissolved in dioxane/water 3:1 (13.5 mL/4.5 mL) in a micfrowave
vial. 2-Chloropyridine-4-boronic acid (354 mg, 2.25 mmol) and
K2CO3 (622 mg,4.5 mmol)wereadded.Themixture was degassed
with N2 for 5 minutes before Pd(PPh3)4 (34.7 mg, 30.0 mmol) was
added. The reaction mixture was heated in the microwave for
30 minutes at 150uC. The solution was concenftrated under
reduced pressure, and the residue was dissolved in dichloro-
methane and filtered through Celite. The filtrate was concentrated
under reduced pressure and the crude product was purified by flash
column chromatography on silica gel (hexane: ethyl acetate=4: 1)
yielding 2 (76%, 418 mg) as a white solid.
1H NMR (CDCl3): d 8.42
(1H, d, J=5.0 Hz), 7.46–7.42 (2H, m), 7.30 (3H, m), 7.03 (6H, m),
5.47 (2H, s).
13C NMR: d 162.9 (d, C-F J=248 Hz), 159.9, 152.7,
150.7, 145.0, 139.3, 129.2, 128.9 (d, C-F J=8.5 Hz), 128.8, 127.4,
126.0 (d, C-F J=3.1 Hz), 125.1, 123.2, 116.0 (d, C-F J=21.5 Hz),
52.9. HRMS [M+1]
+ calculated for C20H15ClFN4
+: 365.0964;
found 365.0959.
4-(1-benzyl-4-phenyl-1H-1,2,3-triazol-5-yl)-2-chloropyri-
dine (3b). T h et r i a z o l eh a l i d e( 3 1 5 m g ,0 . 8 7 m m o l )w a s
dissolved in dioxane/water 3:1 (9 mL/3 mL) in a microwave
vial. 2-Chloropyridine-4-boronic acid (206 mg, 1.3 mmol) and
K2CO3 (362 mg, 2.6 mmol) were added. The mixture was
degassed with N2 for 5 minutes before Pd(PPh3)4 (20.2 mg,
17.4 mmol) was added. The reaction mixture was heated in
the microwave for 30 minutes at 150uC. The solution was con-
fcentrated under reduced pressure and the residue was dissolved
in dichloromethane and filtered through Celite. The filtrate was
concentrated under reduced pressure and the crude product was
purified by flash column chromatography on silica gel (hexane:
ethyl acetate=4: 1) yielding 2 (89%, 268.9 mg) as a white solid.
1H NMR (CDCl3): d 8.41 (1H, dd, J=5.1 Hz, 0.6 Hz), 7.48–
7.46 (2H, m), 7.29–7.32 (6H, m), 7.06 (1H, m), 7.02–7.04 (2H,
m ) ,6 . 9 6( 1 H ,d d ,J=5.1 Hz, 1.5 Hz), 5.47 (2H, s).
13C NMR: d
152.3, 150.4, 145.6, 139.3, 134.5, 129.7, 129.6, 128.9, 128.7,
128.6, 128.4, 127.2, 126.9, 125.0, 123.1, 52.7. HRMS [M+1]+
calculated for C20H16ClN4
+: 347.1058; found 347.1047.
General procedure for Hartwig-Buchwald C-N bond coup-
ling. An oven-dried microvial was charged with Pd(OAc)2 (1
mol%), 2-biphenylcyclohexylphosphine (2 mol%), NaOtBu (1.4
eq.), and compound 2 (1 eq). The vial was sealed with a cap,
evacuated, and filled with N2. Dry toluene (0.5 ml) and amine (1.5
eq.) were added through the septum. The reaction mixture was
heated at 100uC for the specified time. The reaction mixture was
diluted with CH2Cl2 (2 ml) and filtered through Celite. The filtrate
was concentrated under reduced pressure and the residue was
purified on SP-4.
4-(1-benzyl-4-phenyl-1H-1,2,3-triazol-5-yl)-N-isopropylp-
yridin-2-amine (4a). Compound 4a was prepared according to
the general procedure with a reaction time of 3 hours. The crude
product was purified by flash column chromatography on silica gel
(hexane:ethyl acetate=2:1) yielding 4a (68%, 39.2 mg) as a white
solid.
1H NMR (CDCl3): d 8.11 (d, 1H, J=5.1 Hz), 7.60 (m, 2H),
7.28 (m, 6H), 6.34 (dd, 1H, J=5.1 Hz, 1.2 Hz), 6.01 (s, 1H), 5.44
(2H, s), 4.55 (d, 1H, J=7.7 Hz), 3.61 (m, 1H), 1.11 (d, 6H,
J=6.4 Hz).
13CN M R :d 158.5, 149.6, 144.8, 137.6, 135.5, 132.4,
130.5, 128.9, 128.7, 128.3, 128.1, 127.5, 126.9, 112.9, 107.3 2,
52.3, 43.2, 22.9. HRMS [M+1]
+ calculated for C23H24N5
+:
370.2026; found 370.2007.
4-(1-benzyl-4-(4-fluorophenyl)-1H-1,2,3-triazol-5-yl)-N-iso-
propyl-pyridin-2-amine (4b). Compound 4b was prepared
according to the general procedure with a reaction time of 3 hours.
The crude product was purified by flash column chromatography
on silica gel (hexane: ethyl acetate=2: 1) yielding 4a (68%,
39.2 mg) as a white solid.
1H NMR (CDCl3): d 8.13 (dd, 1H,
J=5.1 Hz, 0.7 Hz), 7.57 (m, 2H), 7.27–6.95 (m, 7H, aromatic H),
6.33 (dd, 1H, J=5.1 Hz, 1.4 Hz) 5.98 (s, 1H), 5.44 (2H, s), 4.57 (d,
1H, J=7.9 Hz), 3.61 (m, 1H), 1.12 (d, 6H, J=6.4 Hz).
13C NMR:
d 162.5 (d, C-F J=248 Hz), 158.6, 149.7, 144.0, 137.4, 135.4,
132.2, 128.9, 128.5 (d, C-F J=8.5 Hz), 128.4, 127.5, 126.7 (d, C-F
J=3.1 Hz), 115.5 (d, C-F J=21.5 Hz), 112.8, 107.2, 52.4, 43.2,
22.9. HRMS [M+1]
+ calculated for C23H23FN5
+: 388.1932; found
388.1850.
4-(1-benzyl-4-(4-fluorophenyl)-1H-1,2,3-triazol-5-yl)-N-iso-
propyl-pyridin-2-amine (4c). Compound 4c was prepared
according to the general procedure with a reaction time of 3
hours. The crude product was purified by flash column chro-
matography on silica gel (hexane:ethyl acetate=2:1) yielding 4c
(74%, 41.6 mg) as a yellow oil.
1H NMR (MeOD3): d 8.17 (dd,
J=0.7, 5.2 Hz, 1H), 7.47 (m, 2H), 7.25 (m, 3H), 7.07-7.00 (m, 4H),
6.76 (dd,J=1.4,5.2 Hz,1H), 6.68 (dd,J=0.7,1.3 Hz,1H),5.56 (s,
2H),4.23(dd,J=10.5,4.5 Hz,1H),4.07 (dd,J=10.5,7.4 Hz,1H),
3.30 (m, 1H), 1.16 (d, 3H).
13C NMR (MeOD3): d 165.6, 164.2 (d,
C-F J=247 Hz), 149.3, 145.6, 140.1, 136.5, 133.0, 130.3 (d, C-F
J=8.5 Hz), 129.9, 129.4, 128.5, 127.6 (d, C-F J=3.1 Hz), 119.1,
116.7 (d, C-F J=22.3 Hz), 113.2, 72.7, 53.6, 47.0, 19.0. HRMS
[M+1]
+ calculated for C23H23FN5O
+: 404.1881.
4-(1-benzyl-4-(4-fluorophenyl)-1H-1,2,3-triazol-5-yl)-N-(4-
methyl-cyclohexyl)pyridin-2-amine (4d). Compound 4dwas
prepared according to the general procedure with a reaction time
of 24 hours. The crude product was purified by flash column
chromatography on silica gel (toluene:ethyl acetate=97:3) yielding
4d (70%, 85.2 mg) as a white solid.
1H NMR (CDCl3): d 8.12 (app.
t, 1H), 7.58 (m, 2H), 7.29–6.97 (m, 7H, aromatic H), 6.32 (m, 1H),
5.97 (d, 1H, J=6.3 Hz), 5.44 (2H, s), 1.90 (m, 1H), 1.68–0.86 (m,
13H).
13C NMR: d 162.6 (d, C-F J=247 Hz), 158.6, 149.7, 143.9,
137.4, 135.4, 132.2, 128.9, 128.7 (d, C-F J=7.7 Hz), 128.4, 127.4,
126.7 (d, C-F J=3.1 Hz), 115.7 (d, C-F J=21.5 Hz), 112.7, 107.0,
52.4, 50.6, 46.9, 33.9, 33.2, 32.1, 30.8, 29.7 and 29.2, 22.3. HRMS
[M+1]
+ calculated for C27H29FN5
+: 442.2402; found 442.2420.
(S)-4-(1-benzyl-4-(4-fluorophenyl)-1H-1,2,3-triazol-5-yl)-N-
(1-phenylethyl)pyridin-2-amine (4e). Compound 4e was pre-
pared according to the general procedure with a reaction time
of 70 hours. The crude product was purified by flash column
chromatography on silica gel (heptane:ethyl acetate=4:1) yielding
4e (64%, 79.2 mg) as yellow solid.
1H NMR (CDCl3): d 8.07 (app.
d, 1H), 7.43 (m, 2H), 7.32–7.19 (m, 8H, aromatic H), 6.93–6.88 (m,
4H, aromatic H), 6.21 (dd, 1H, J=5.1 Hz, 1.4 Hz), 5.96 (s, 1H),
5.45 (d, J=5.6 Hz, 1H), 4.94–5.36 (m, 2H), 4.53 (m, 1H), 1.52 (d,
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13CN M R :d 162.6 (d, C-F J=248 Hz), 158.4,
149.5,144.0,144.0, 137.4, 135.1, 132.0, 128.9,128.8,128.7(d,C-F
J=7.7 Hz), 128.3, 127.6 (d, C-F J=3.1 Hz), 127.5, 126.5, 125.8,
115.6 (d, C-F J=21.5 Hz), 113.5, 107.2, 52.2, 52.1, 24.4. HRMS
[M+1]
+ calculated for C28H25FN5
+: 450.2089; found 450.2087.
Yeast strains and plasmids
The following Saccharomyces cerevisiae strains were used: BY4741
wild-type (MATa his3D1 leu2D0 met15D0 ura3D0), BY4741
pdr5D::KanMX, BY4741 hog1D::KanMX, BY4743 (MATa/MATa
his3D0/his3D0 leu2D/leu2D0 met15D0/MET15 LYS2/lys2D0
ura3D0/ura3D0), W303-1A (MATa, leu23/112 ura31 trp11 his311/
15 ade21 can1100 GAL SUC2), YSH818 (W303-1A hog1D::LEU2),
W303-1A-STL1-lacZ (MATa, leu23/112 ura31 trp11 his311/15
ade21 can1100 GAL SUC2 STL1-lacZ-URA3), and SO329 (MATa
can1 his4 leu2 trp1 ura3-52 FUS1-lacZ-LEU2). The plasmid
containing GFP-tagged Hog1 was constructed by digesting the
plasmid pRV-65
wt [41] with BamHI and HindIII and cloning the
resulting 2.5 kb fragment containing HOG1-GFP into YCplac33
(CEN, URA3). The gToW plasmids pSBI40, gToW-PBS2 and
gToW-SSK1 have been described previously [32].
Plate halo assay
Wt and pdr5D cells were grown in YPD (1% yeast extract, 2%
peptone, 2% glucose) medium until mid-log phase and mixed with
low melting agarose and YPDA (YPD supplemented with 0.3%
adenine) with or without 1.5 M sorbitol. The cell mixture was
poured onto YPDA plates with or without 1.5 M sorbitol and
allowed to solidify. Filter discs soaked with 5 ml inhibitor (or
DMSO for the controls) in various concentrations were placed on
top of the lawn of cells. The plates were incubated at 30uC and
growth was scored after 1–2 days.
Liquid medium micro-cultivation
Yeast strains (BY4743 background) were grown for 72 hours in
the presence or absence of the indicated concentrations of
inhibitor using a high-resolution micro-cultivation approach as
previously described [32,42]. Wt and hog1D cells were transformed
with the empty gToW plasmid pSBI40 or the same plasmid
overexpressing PBS2 or SSK1 [32].
Cell extracts and immunoblotting
Wild-type cells were grown in YPD to an OD600 of approx-
imately 1. The cultures were then incubated with the inhibitor, or
the corresponding volume of DMSO as a control, for 15 minutes
before applying the osmotic stress. Sorbitol, dissolved in YPD, was
added to the cultures to a final concentration of 0.8 M. The
corresponding volume of YPD was added to the control cultures.
Samples (1 ml) were taken at 0, 15, 30, 60, and 120 minutes, spun
down, resuspended in 50 ml protein extraction buffer (0.1 M Tris
Cl, pH 6.8; 4% SDS; 20% glycerol; 0.2 M DTT; 10 mM NaF;
0.1 mM Na3VO4; protease inhibitor cocktail; 0.2 M b-mercapto-
ethanol), and boiled for 10 minutes. Proteins were separated on a
7.5% SDS-PAGE gel and transferred to a nitrocellulose
membrane. The membrane was saturated in Odyssey blocking
buffer (Li-Cor Biosciences, Lincoln, NE) for 45 minutes at room
temperature and then incubated overnight at 4uC with a rabbit
monoclonal anti-phospho-p38 antibody (Cell Signaling Technol-
ogy, Danvers, MA). After 365 minute washes in TBS (138 mM
NaCl, 2.7 mM KCl, 5 mM Tris base) with 0.1% Tween, the
membrane was incubated with a goat polyclonal anti-Hog1 (yC-
20) antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) for
one hour at room temperature. The membrane-bound antibodies
were detected with secondary IRDye 800CW donkey anti-rabbit
and IRDye 680 donkey anti-goat antibodies (Li-Cor Biosciences,
Lincoln, NE) and visualized with an Odyssey infrared imaging
system (Li-Cor Biosciences, Lincoln, NE).
Measurement of reporter gene expression
Exponentially growing cells harboring either the STL1-lacZ or
FUS1-lacZ reporter constructs were pretreated with the inhibitor
or DMSO for 10 minutes followed by the addition of 0.8 M
sorbitol or 10 mM a-factor. Cells were harvested, and b-galac-
tosidase activities of the protein extracts were assayed according to
the literature [43].
In vitro Hog1 kinase assays
Kinase assays were performed in 384-well plate format using
purified GST-tagged Hog1 and the biotinylated peptide (biotin)-
DVPG-T-PSDKVITF as a substrate, where the peptide se-
quence corresponds to the sequence in Sic1 that is targeted and
phosphorylated by Hog1. Hog1 was activated in vitro using a
constitutively active upstream kinase (GST-Pbs2EE), as described
previously [14,44]. To the reaction wells, 2 ml of the inhibitor in
10% DMSO were added at the desired concentrations; the final
concentration of DMSO in all reactions was 1%. A kinase reaction
master mix was prepared and added in 18 ml aliquots to the wells;
thereafter the plate was incubated in a water bath for 4 hours at
37uC with agitation. The final concentrations in the reactions
were: 0.02 mg/ml active Hog1, 100 mM substrate peptide, 0.2 mM
ATP, and 0.1 mCi/nmol [
32cP]-ATP in a kinase buffer (50 mM
Tris-HCl, pH 7.5, 10 mM MgCl2, 2 mM DTT). After incubation,
2 ml of each reaction was transferred to a SAM2 membrane
(Promega, V7861), which was washed and dried as previously
described [45]. The membrane was then exposed to a Phosphor-
Imager screen and subsequently imaged in a Molecular ImagerH
FX (BioRad). To quantify the kinase activity in the assays, the
density of the signal from each spot on the membrane was
determined (QuantityOne-4.6.8; Bio-Rad Laboratories). For the
inhibition curves (Figure 4B), the initial sample of each series
(0.1 nM inhibitor) was set to 100% activity, whereas in the
comparative study (Figure 4A), a reference reaction with 1%
DMSO was used as a null sample. For the calculation of the
IC50 values, a four-parameter model in BioDataFit 1.02 (www.
changbioscience.com) was used.
Cell cycle experiments
To analyze the G1/S checkpoint during As(III) stress, yeast cells
synchronized in G1 with 5 mM a-factor were released into fresh
YPDA medium containing 0.5 mM As(III) in the presence or
absence of 1 mM of inhibitor. In control experiments, G1-arrested
cells were released into a medium lacking As(III) in the presence or
absence of 1 mM of inhibitor. Samples were collected at 20-minute
intervals for the a-factor-nocodazole trap assay to determine the
percentage of cells that remained in G1, and at 30-minute intervals
for Western blotting to monitor dually phosphorylated and total
Hog1. The a-factor-nocodazole trap assay, protein extracts, and
Western analysis were performed as described [20]. All cell cycle
experiments were repeated at least twice, and representative
results are presented.
Chemical Genetic Profiling
Screens were performed essentially as described by Ericson et al,
[46]. Compound doses for the genome-wide screens were
determined by performing a dose response for each compound
and 2% DMSO to serve as the vehicle control. The wild-type
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MATa/a his3D1/his3D1 leu2D0/leu2D0 lys2D0/LYS2 MET15/
met15D0 ura3D0 /ura3D0 ORF::kanMX4) was used to determine
the dose of compound that resulted in 15% growth inhibition.
Cells were inoculated at an OD600 of 0.0625 in serial dilutions of
drug and grown in a Tecan GENios microplate reader (Tecan
Systems Inc., San Jose, USA) at 30uC with orbital shaking. Optical
density measurements (OD600) were taken every 15 minutes until
the cultures were saturated, and doubling time (D) was calculat-
ed as described [47]. For genome-wide fitness profiles, ,4700
homozygous deletion strains and ,1100 essential heterozygous
deletion strains were assayed as described [46] combining 5-
generation homozygous pools and 350 ml from the 20-generation
heterozygous essential pool prior to genomic DNA extraction.
200 ng of genomic DNA was added to 2 separate PCR reactions,
one each with primers designed to amplify all UPTAGs and
DOWNTAGS. One primer in each reaction was biotinylated such
that it could be detected following hybridization using streptavi-
din-phycoerythrin. Intensity values for the probes on the chip were
extracted using the GeneChip Operating Software (Affymetrix).
Quantile normalization, outlier omission, fitness defect ratios
performed as previously described [47]. The larger the ratio, the
more depleted (sensitive) is the strain as compared to control
condition without the drug.
Supporting Information
Figure S1 Plate halo assay: Compound 4a, 4b, and SB-
203580. SB203580 does not enter yeast cells. A lawn of yeast cells
that lack the major multidrug export protein Pdr5 (pdr5D) was
spread on solid medium in the absence (control) or presence of
osmotic stress (1.5 M sorbitol), and filter discs containing various
concentrations of 4a, 4b, and SB203580 were placed on top of
the lawn. Inhibition of Hog1 activity can be visualized by the
formation of a halo of non-proliferating cells around the filter discs
in the presence of osmotic stress (1.5 M sorbitol). No such halo is
visible on control plates. Plates were incubated for 48 hours at
30uC.
(TIF)
Figure S2 Plate halo assay: Commercially available p38
inhibitors. Commercially available p38-inhibitors do not enter
yeast cells. A lawn of wild type yeast cells was spread on solid
medium in the absence (control) or presence of osmotic stress
(1.5 M sorbitol), and filter discs containing 2 mM of the indicated
inhibitors were placed on top of the lawn. Inhibition of Hog1
activity can be visualized by the formation of a halo of non-
proliferating cells around the filter discs in the presence of osmotic
stress (1.5 M sorbitol). No such halo is visible on control plates.
Plates were incubated for 48 hours at 30uC.
(TIF)
Figure S3 Phosphorylation of a kinase-dead Hog1 allele
(Hog1
K52R). Sustained phosphorylation of a kinase-dead Hog1
allele (Hog1
K52R) in response to osmotic stress. hog1D cells were
transformed with a plasmid containing the kinase-dead Hog1
K52R
allele. Phosphorylation was monitored in cells exposed to osmotic
stress (0.4 M NaCl) by western blot analysis using an antibody
specific to dually phosphorylated p38 MAPK, and an anti-Hog1
antibody as a control.
(TIF)
Figure S4 Inhibition of Hog1-dependent gene expres-
sion (STL1-lacZ). Inhibition of Hog1-dependent gene expres-
sion. Exponentially growing cells harboring the STL1-lacZ reporter
were exposed to osmotic stress (0.8 M sorbitol) and assayed for b-
galactosidase activity as described in the Experimental section.
Induced expression of the STL1 gene by osmotic stress requires
Hog1. 4b was added to cells at the indicated concentrations
10 minutes before osmotic stress was applied. The results are the
average of three independent experiments and the error bars
represent standard deviation (s.d.).
(TIF)
Figure S5 Hog1 kinase activity required to relieve
As(III)-induced G1 checkpoint arrest. Hog1 kinase activity
is required to relieve As(III)-induced G1 checkpoint arrest. (A)
HOG1 deletion or addition of 4a result in persistent G1 arrest in
the presence of As(III). (B) As(III)-induced G1 checkpoint delay can
be prolonged by addition of 4a until just before onset of the S
phase. (C) Removal of 4a quickly relieves G1 arrest. Wild-type
(W303-1A) and the isogenic HOG1 deletion mutant (hog1D) were
synchronized in G1 with 5 mM a-factor and released in fresh
medium in the presence or absence of 0.5 mM sodium arsenite
[As(III)]. 4a (1 mM) was added as indicated. After washing out the
inhibitor (in C), the cells were resuspended in fresh medium
containing 0.5 mM As(III). The percentage of cells that remained
in G1 was determined by the a-factor-nocodazole trap assay.
(TIF)
Figure S6 4a improves growth of PBS2 and SSK1
overexpressing cells. 4a improves growth of PBS2 and SSK1
overexpressing cells. Wild-type and hog1D cells (BY4743 strain)
were transformed with an empty plasmid or plasmids overex-
pressing PBS2 or SSK1. Cells were grown in a micro-cultivation
system in the absence or presence of inhibitor as indicated.
(TIF)
Figure S7 4b improves growth of PBS2 and SSK1
overexpressing cells. 4b improves growth of PBS2 and SSK1
overexpressing cells. Wild-type and hog1D cells (BY4743 strain)
were transformed with an empty plasmid or plasmids overex-
pressing PBS2 or SSK1. Cells were grown in a micro-cultivation
system in the absence or presence of inhibitor as indicated.
(TIF)
Table S1 Selectivity. Chemical genetic profiling of the yeast
deletion mutant collection in the presence of 500 mM 4a.
(XLS)
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